Get notified of page updates
Research & Clinical Trials > Featured Research

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

Opening the Conversation

Opening the Conversation

Clinicaltrials.gov identifier:
NCT04806724

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

Clinicaltrials.gov identifier:
NCT05169437

Treatment
Any advanced or metastatic solid tumor except ovarian or prostate

Men at High Genetic Risk for Prostate Cancer

Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention
Prostate screening with MRI for men with Lynch syndrome or a BRCA1/2, ATM, BRIP1, CHEK2, PALB2, RAD51C/D, TP53, HOXB13, FANCA or NBN mutation

Pancreatic Cancer Early Detection for People  at High Risk

Pancreatic Cancer Early Detection for People at High Risk

Clinicaltrials.gov identifier:
NCT04970056

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer

Pancreatic Cancer Screening Study(CAPS5)

Pancreatic Cancer Screening Study(CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Clinicaltrials.gov identifier:
NCT03462342

Treatment
Recurrent ovarian cancer

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

Clinicaltrials.gov identifier:
NCT04837820

Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer

Restoring Sensation after DIEP Flap Reconstruction

Restoring Sensation after DIEP Flap Reconstruction

Clinicaltrials.gov identifier:
NCT04533373

Prevention
Study for people undergoing DIEP flap reconstruction

Denosumab for Preventing Breast Cancer in Women with a BRCA1 Inherited Mutation (BRCA-P)

Denosumab for Preventing Breast Cancer in Women with a BRCA1 Inherited Mutation (BRCA-P)

Clinicaltrials.gov identifier:
NCT04711109

Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation

Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT05505045

Quality of Life
Telehealth study for breast cancer survivors with memory issues

Differences in Family Communication about Positive Genetic Test Results Between Asian Americans

Differences in Family Communication about Positive Genetic Test Results Between Asian Americans

Surveys, Registries, Interviews
Interview for Asian Americans with a mutation in BRCA1, BRCA2, ATM, CHEK2, PALB2 or other gene linked to breast or ovarian cancer risk

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

Clinicaltrials.gov identifier:
NCT04262180

Quality of Life
Exercise study for breast or endometrial cancer survivors

Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family

Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family

Surveys, Registries, Interviews
Women with a BRCA mutation or from a family with a BRCA mutation

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors

Clinicaltrials.gov identifier:
NCT05056077

Quality of Life
Nonmetastatic colon or rectal cancer

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Clinicaltrials.gov identifier:
NCT05129605

Prevention
People at high risk for prostate cancer due to an inherited mutation

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05252390

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Assessing Decisions about Uterine and Ovarian Cancer Prevention by People with Lynch Syndrome

Assessing Decisions about Uterine and Ovarian Cancer Prevention by People with Lynch Syndrome

Surveys, Registries, Interviews
Online survey for people with Lynch syndrome

Opening the Conversation Study

Opening the Conversation Study

Clinicaltrials.gov identifier:
NCT04806724

Quality of Life
Videoconference sessions that address cancer related concerns for couples

Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

Clinicaltrials.gov identifier:
NCT03317392

Treatment
People with castration-resistant prostate cancer with bone spread

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

Clinicaltrials.gov identifier:
NCT04455750

Treatment
Treatment study for men with metastatic prostate cancer

Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

Clinicaltrials.gov identifier:
NCT04621721

Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy

Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors

Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT05364450

Quality of Life
People with stage 1-3 breast cancer who completed treatment within 5 years of enrollment

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Clinicaltrials.gov identifier:
NCT04038502

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women

Clinicaltrials.gov identifier:
NCT05287451

Prevention
Prevention study for women at high risk for ovarian cancer

Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair

Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair

Clinicaltrials.gov identifier:
NCT03012321

Treatment
Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

Clinicaltrials.gov identifier:
NCT04497844

Treatment
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results

Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results

Surveys, Registries, Interviews
Survey and video interview for people who tested positive for an inherited mutation

Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation

Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation

Surveys, Registries, Interviews
Survey for people with a BRCA1 or BRCA2 mutation

Bazedoxifene Plus Conjugated Estrogens for Hot-Flashes in Women at High Risk for Breast Cancer

Bazedoxifene Plus Conjugated Estrogens for Hot-Flashes in Women at High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT04821141

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot-flashes

Interview Study about Barriers to Genetic Testing of Family Members in Latin America

Interview Study about Barriers to Genetic Testing of Family Members in Latin America

Surveys, Registries, Interviews
People with a hereditary cancer gene mutation and relatives living in Latin America

Research Opportunity for Previvors and their Romantic Partners

Research Opportunity for Previvors and their Romantic Partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT04906200

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39

BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

Combination Drugs for Treating Metastatic Castration-resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair

Combination Drugs for Treating Metastatic Castration-resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair

Clinicaltrials.gov identifier:
NCT03012321

Treatment
Treatment study for men with metastatic castration-resistant prostate cancer

Zoom Interviews to Explore Ideas about Long-Term Follow-Up Cancer Genetic Counseling

Zoom Interviews to Explore Ideas about Long-Term Follow-Up Cancer Genetic Counseling

Surveys, Registries, Interviews
Interviews with adults that have recently met with a cancer genetic counselor in the U.S., regardless of genetic testing outcome

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Metastatic Pancreatic Cancer in US

Metastatic Pancreatic Cancer in US

Surveys, Registries, Interviews
People with metastatic pancreatic cancer and their caregivers

Interviews for people with a genetic test result that was later reclassified

Interviews for people with a genetic test result that was later reclassified

Surveys, Registries, Interviews
People with a genetic test result that was later reclassified

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer (AVPC)

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer (AVPC)

Clinicaltrials.gov identifier:
NCT04592237

Treatment
Treatment in people with aggressive metastatic prostate cancer

All of Us Research Program

All of Us Research Program

Surveys, Registries, Interviews
Anyone age 18 or over

Studying Crowdfunding for Cancer

Studying Crowdfunding for Cancer

Surveys, Registries, Interviews
Cancer survivors who have used crowdfunding to help cover cancer-related costs

Treating Early-Stage Breast Cancer  with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with  a BRCA or PALB2 Mutation

Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04584255

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Clinicaltrials.gov identifier:
NCT04644068

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Interview about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk

Interview about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk

Surveys, Registries, Interviews
Hispanic/Latino people with a personal diagnosis of cancer or a family history of cancer

ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04267939

Treatment
Advanced ovarian cancer or other solid tumors

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

Clinicaltrials.gov identifier:
NCT03231891

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Clinicaltrials.gov identifier:
NCT04548752

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

Testing  a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04367675

Prevention
People with a BRCA1 or BRCA2 mutation

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment
Advanced solid tumors

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib

Clinicaltrials.gov identifier:
NCT03337087

Treatment
Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Clinicaltrials.gov identifier:
NCT03607890

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Fear of Recurrence, Adversity, and Pain

Fear of Recurrence, Adversity, and Pain

Surveys, Registries, Interviews

Blood Markers of Early Pancreas Cancer

Blood Markers of Early Pancreas Cancer

Clinicaltrials.gov identifier:
NCT03568630

Prevention
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

Metastatic Prostate Cancer Project

Metastatic Prostate Cancer Project

Surveys, Registries, Interviews

The Metastatic Breast Cancer Project

The Metastatic Breast Cancer Project

Surveys, Registries, Interviews

Connect My Variant

Connect My Variant

Surveys, Registries, Interviews

Study for People with Unexpected Genetic Results

Study for People with Unexpected Genetic Results

Clinicaltrials.gov identifier:
NCT02595957

Prevention

ELLIE's Project

ELLIE's Project

Quality of Life

Find My Variant

Find My Variant

Surveys, Registries, Interviews

Pancreatic Cancer Early Detection

Pancreatic Cancer Early Detection

Clinicaltrials.gov identifier:
NCT02206360

Prevention

WISDOM Study

WISDOM Study

Clinicaltrials.gov identifier:
NCT02620852

Prevention

PROMPT

PROMPT

Clinicaltrials.gov identifier:
NCT02665195

Surveys, Registries, Interviews



Sponsored By:

Merck & Co., Inc.
Mike & Patti Hennessy Foundation